

## United States Patent and Trademark Office

CK

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,468	11/21/2003	George P. Sakalosky	14066.03	2597
759	90 06/02/2005		EXAMINER	
Scott D. Rothe DORSEY & WI		WEDDINGTON, KEVIN E		
Suite 1500	MINEI EEI	ART UNIT	PAPER NUMBER	
50 South Sixth S	Street	1614		
Minneapolis, M	IN 55402-1498	DATE MAILED: 06/02/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

<del>, , , , , , , , , , , , , , , , , , , </del>	<del></del>	Application	in No.	Applicant(s)			
Office Action Summary		10/719,46		SAKALOSKY, GEORGE P.			
		Examiner		Art Unit			
•	•	Kevin E. W	/eddinaton	1614			
	The MAILING DATE of this communicat				dress		
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)[🛛	Responsive to communication(s) filed o	n 17 February 200	95.				
2a)□	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.						
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)  Claim(s) 3-21 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5)  Claim(s) is/are allowed.  6)  Claim(s) 3-21 is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) are subject to restriction and/or election requirement.							
Applicati	ion Papers						
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
•	·						
Priority under 35 U.S.C. § 119  12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
Attachmen	t(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  Paper No(s)/Mail Date							
3) Infor	ee of Draftsperson's Patent Drawing Review (PTO- mation Disclosure Statement(s) (PTO-1449 or PTC er No(s)/Mail Date	·	Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:		O-152)		

Application/Control Number: 10/719,468

Art Unit: 1614

Claims 3-21 are presented for examination.

Applicants' amendment filed February 17, 2005 has been received and entered.

Accordingly, the rejections made under Obviousness-type double patenting, 35 USC 112, first paragraph and 35 USC 102 a set forth in the previous Office action dated August 17, 2004 at pages 2-5 as applied to claims 1-21 are hereby withdrawn.

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See-In re-Goodman, 11-F.3d 1046,-29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 3-21 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 6,660,762. Although the conflicting claims are not identical, they are not patentably distinct from each other because the present application teach a packaged pharmaceutical composition comprising an container that

Art Unit: 1614

holds a therapeutically effective amount of at least one porphyrin analogue and pharmaceutically acceptable salts, esters, amides and prodrugs thereof and administered as an aerosol (A Product); and the patented application teaches a method to treat a subject having berylliosis comprising the step of administering to the subject the said instant pharmaceutical composition of the present application therein which makes the instant pharmaceutical composition claims of the present application an obvious variation of the patented claims.

Claims 3-21 are not allowed.

Any inquiry concerning this communication or earlier communications from the examiner-should-be directed to Kevin E. Weddington whose telephone number is (571) 272-0587. The examiner can normally be reached on 11:00 am-7:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/719,468 Page 4

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin E. Wedding Primary Examiner Art Unit 1614

K. Weddington May 30, 2005